Keeping Track: Shutdown Edition

The latest drug development news and highlights from our US FDA Performance Tracker.

Keeping Track Feature image

While the United States government shut down lasted only one business day, review and approval events in the biopharma world seem to have experience a more extended lapse. Yes, it was a slow week, but there was still enough news that it needs to be presented in brief:

The US FDA gave its blessing to Advanced Accelerator Applications SA's Lutathera (lutetium Lu 177 dotatate), marking the agency's...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Product Reviews

Recent And Upcoming FDA Advisory Committee Meetings

 
• By 

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

Rese-Cel CAR T Therapy Secures EMA PRIME Designation

 

Cabaletta’s rese-cel is among the latest investigational drugs that have won a place on the European Medicines Agency priority medicines scheme. Meanwhile, 11 products were denied PRIME designations.

October US FDA User Fee Goals: Few Novel Agents, But Many New Indications As Shutdown Looms

 

October is unusually low on user fee goals for novel agents, but more than 20 applications for new indications and formulations will keep FDA staff busy, especially in oncology and ophthalmology.

OMUFA Reauthorization: US FDA Would Identify Rx-OTC Switch Candidates, Work With Sponsors

 
• By 

The Senate “SMART OTC” Act would require the FDA to identify product categories that could be eligible for an Rx-to-OTC switch and create a framework to work with sponsors.

More from Pink Sheet

‘Chubby Labels?’: Generic Entresto Approval Was Lawful, D.C. Appeals Court Finds

 
• By 

MSN Laboratories wins another case against Novartis and will keep approval for its generic version of Entresto. The decision effectively confirms that US FDA can approve ANDA labels that make limited wording changes to carve around patent-protected indications, reinforcing the agency’s flexibility.

EU Pharma Package: Keep Patients Front & Center In Defining Unmet Medical Need

 

EU trilogs on the new pharmaceutical legislation will finalize the role patients will take in influencing the development of a new definition of unmet medical need.

CDC Should Boost Vaccine Monitoring Transparency, Communication - National Academies Report

 
• By 

The Immunization Safety Office leveraged a “coordinated network of complementary surveillance systems” to monitor COVID-19 vaccine risks during the pandemic, but its communications faced challenges and were often intertwined with CDC efforts to promote vaccination, NASEM report finds.